請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62782
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃佩欣 | |
dc.contributor.author | Hsin-Yi Huang | en |
dc.contributor.author | 黃馨儀 | zh_TW |
dc.date.accessioned | 2021-06-16T16:10:16Z | - |
dc.date.available | 2016-09-24 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-03-04 | |
dc.identifier.citation | PART I (p.28)
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554. Bagri, A., and Tessier-Lavigne, M. (2002). Neuropilins as Semaphorin receptors: in vivo functions in neuronal cell migration and axon guidance. Adv Exp Med Biol 515, 13-31. Bagri, A., Tessier-Lavigne, M., and Watts, R. J. (2009). Neuropilins in Tumor Biology. Clin Cancer Res 15, 1860-1864. Bamberg J.A., Baumgartner S., Betz H., Bolz J., Chedotal A., Christensen C.R.L., Comoglio P.M., Culotti J.G., Doherty P., Drabkin H., et al (1999). Unified Nomenclature for the Semaphorins/Collapsins. Cell 97, 551-552. Baumgart M, Heinmöller E, Horstmann O, Becker H, and BM., G. (2005). The genetic basis of sporadic pancreatic cancer. Cell Oncol 27, 3-13. Bergsland, M., Werme, M., Malewicz, M., Perlmann, T., and Muhr, J. (2006). The establishment of neuronal properties is controlled by Sox4 and Sox11. Genes & Development 20, 3475-3486. Bhattaram, P., Penzo-Mendez, A., Sock, E., Colmenares, C., Kaneko, K. J., Vassilev, A., DePamphilis, M. L., Wegner, M., and Lefebvre, V. (2010). Organogenesis relies on SoxC transcription factors for the survival of neural and mesenchymal progenitors. Nat Commun 1, 9. Bielenberg, D., and Klagsbrun, M. (2007). Targeting endothelial and tumor cells with semaphorins. Cancer and Metastasis Reviews 26, 421-431. Castillo, S. D., Matheu, A., Mariani, N., Carretero, J., Lopez-Rios, F., Lovell-Badge, R., and Sanchez-Cespedes, M. (2012). Novel Transcriptional Targets of the SRY-HMG Box Transcription Factor SOX4 Link Its Expression to the Development of Small Cell Lung Cancer. Cancer research 72, 176-186. Chedotal, A., Kerjan, G., and Moreau-Fauvarque, C. (2005). The brain within the tumor: new roles for axon guidance molecules in cancers. Cell Death Differ 12, 1044-1056. Christensen, C., Ambartsumian, N., Gilestro, G., Thomsen, B., Comoglio, P., Tamagnone, L., Guldberg, P., and Lukanidin, E. (2005). Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer research 65, 6167-6177. Chung, L., Yang, T.-L., Huang, H.-R., Hsu, S.-M., Cheng, H.-J., and Huang, P.-H. (2007). Semaphorin signaling facilitates cleft formation in the developing salivary gland. Development 134, 2935-2945. de Bont, J. M., Kros, J. M., Passier, M. M. C. J., Reddingius, R. E., Smitt, P. A. E. S., Luider, T. M., Boer, M. L. d., and Pieters, R. (2008). Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro-Oncology 10, 648-660. Dyrskjøt, L., Ostenfeld, M. S., Bramsen, J. B., Silahtaroglu, A. N., Lamy, P., Ramanathan, R., Fristrup, N., Jensen, J. L., Andersen, C. L., Zieger, K., et al. (2009). Genomic Profiling of MicroRNAs in Bladder Cancer: miR-129 Is Associated with Poor Outcome and Promotes Cell Death In vitro. Cancer research 69, 4851-4860. Frierson Jr, H. F., El-Naggar, A. K., Welsh, J. B., Sapinoso, L. M., Su, A. I., Cheng, J., Saku, T., Moskaluk, C. A., and Hampton, G. M. (2002). Large Scale Molecular Analysis Identifies Genes with Altered Expression in Salivary Adenoid Cystic Carcinoma. The American Journal of Pathology 161, 1315-1323. Fu, B., Luo, M., Lakkur, S., Lucito, R., and Iacobuzio-Donahue, C. A. (2008). Frequent genomic copy number gain and overexpression of GATA-6 in pancreatic carcinoma. Cancer Biology & Therapy 7, 1593-1601. Gaur, P., Bielenberg, D. R., Samuel, S., Bose, D., Zhou, Y., Gray, M. J., Dallas, N. A., Fan, F., Xia, L., Lu, J., and Ellis, L. M. (2009). Role of Class 3 Semaphorins and Their Receptors in Tumor Growth and Angiogenesis. Clinical Cancer Research 15, 6763-6770. Gitler, A. D., Lu, M. M., and Epstein, J. A. (2004). PlexinD1 and Semaphorin Signaling Are Required in Endothelial Cells for Cardiovascular Development. Developmental Cell 7, 107-116. Gu, C., Yoshida, Y., Livet, J., Reimert, D. V., Mann, F., Merte, J., Henderson, C. E., Jessell, T. M., Kolodkin, A. L., and Ginty, D. D. (2005). Semaphorin 3E and Plexin-D1 Control Vascular Pattern Independently of Neuropilins. Science 307, 265-268. Hatziapostolou, M., and Iliopoulos, D. (2011). Epigenetic aberrations during oncogenesis. Cellular and Molecular Life Sciences 68, 1681-1702. Heidenblad, M., David Lindgren, Tord Jonson, Fredrik Liedberg, Srinivas Veerla, Gunilla Chebil, Sigurdur Gudjonsson, Åke Borg, Wiking Månsson, and Höglund, M. (2008). Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Medical Genomics 1, 3. Herman JG, and GG., M. (2007). Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. Int J Oncol 30, 1231-1238. Huang, Y. W., Liu, J. C., Deatherage, D. E., Luo, J., Mutch, D. G., Goodfellow, P. J., Miller, D. S., and Huang, T. H. (2009). Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer research 69, 9038-9046. Hur, E. H., Hur, W., Choi, J. Y., Kim, I. K., Kim, H. Y., Yoon, S. K., and Rhim, H. (2004). Functional identification of the pro-apoptotic effector domain in human Sox4. Biochemical and biophysical research communications 325, 59-67. Ikushima, H., Todo, T., Ino, Y., Takahashi, M., Miyazawa, K., and Miyazono, K. (2009). Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 5, 504-514. Jafarnejad, S. M., Wani, A. A., Martinka, M., and Li, G. (2010). Prognostic Significance of Sox4 Expression in Human Cutaneous Melanoma and Its Role in Cell Migration and Invasion. The American Journal of Pathology 177, 2741-2752. Jiang, S. X., Sheldrick, M., Desbois, A., Slinn, J., and Hou, S. T. (2007). Neuropilin-1 Is a Direct Target of the Transcription Factor E2F1 during Cerebral Ischemia-Induced Neuronal Death In Vivo. Molecular and Cellular Biology 27, 1696-1705. Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008). Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science 321, 1801-1806. Kigel, B., Varshavsky, A., Kessler, O., and Neufeld, G. (2008). Successful Inhibition of Tumor Development by Specific Class-3 Semaphorins Is Associated with Expression of Appropriate Semaphorin Receptors by Tumor Cells. PLoS ONE 3, e3287. Kim, E. J., and Simeone, D. M. (2011). Advances in pancreatic cancer. Current Opinion in Gastroenterology 27, 460-466 Kim, H.-D., Choe, H. K., Chung, S., Kim, M., Seong, J. Y., Son, G. H., and Kim, K. (2011). Class-C SOX Transcription Factors Control GnRH Gene Expression via the Intronic Transcriptional Enhancer. Molecular Endocrinology 25, 1184-1196. Kodo, K., Nishizawa, T., Furutani, M., Arai, S., Yamamura, E., Joo, K., Takahashi, T., Matsuoka, R., and Yamagishi, H. (2009). GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling. Proceedings of the National Academy of Sciences 106, 13933-13938. Kusy, S., Potiron, V., Zeng, C., Franklin, W., Brambilla, E., Minna, J., Drabkin, H. A., and Roche, J. (2005). Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1730, 66-76. Liao, Y. L., Sun, Y. M., Chau, G. Y., Chau, Y. P., Lai, T. C., Wang, J. L., Horng, J. T., Hsiao, M., and Tsou, A. P. (2008). Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene 27, 5578-5589. Lin, B., Madan, A., Yoon, J.-G., Fang, X., Yan, X., Kim, T.-K., Hwang, D., Hood, L., and Foltz, G. (2010). Massively Parallel Signature Sequencing and Bioinformatics Analysis Identifies Up-Regulation of TGFBI and SOX4 in Human Glioblastoma. PLoS ONE 5, e10210. Lioubinski, O., Müller, M., Wegner, M., and Sander, M. (2003). Expression of Sox transcription factors in the developing mouse pancreas. Developmental Dynamics 227, 402-408. Liu, E. T. (2008). Functional genomics of cancer. Current Opinion in Genetics and Development 18, 251-256. Luo, Y., Raible, D., and Raper, J. A. (1993). Collapsin: A protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75, 217-227. Müller, M. W., Giese, N. A., Swiercz, J. M., Ceyhan, G. O., Esposito, I., Hinz, U., Büchler, P., Giese, T., Büchler, M. W., Offermanns, S., and Friess, H. (2007). Association of axon guidance factor Semaphorin 3A with poor outcome in pancreatic cancer. International Journal of Cancer 121, 2421-2433. Medina, P. P., Castillo, S. D., Blanco, S., Sanz-Garcia, M., Largo, C., Alvarez, S., Yokota, J., Gonzalez-Neira, A., Benitez, J., Clevers, H. C., et al. (2009). The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Human Molecular Genetics 18, 1343-1352. Moreno, C. S. (2010). The Sex-Determining Region Y-Box 4 and Homeobox C6 Transcriptional Networks in Prostate Cancer Progression: Crosstalk with the Wnt, Notch, and PI3K Pathways. The American journal of pathology 176, 518-527. Nakamura, F., Tanaka, M., Takahashi, T., Kalb, R. G., and Strittmatter, S. M. (1998). Neuropilin-1 Extracellular Domains Mediate Semaphorin D/III-Induced Growth Cone Collapse. Neuron 21, 1093-1100. Negishi, M., Oinuma, I., and Katoh, H. (2005). Plexins: axon guidance and signal transduction. Cellular and Molecular Life Sciences 62, 1363-1371. Neufeld, G., and Kessler, O. (2008). The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 8, 632-645. Nissen-Meyer, L. S. H., Jemtland, R., Gautvik, V. T., Pedersen, M. E., Paro, R., Fortunati, D., Pierroz, D. D., Stadelmann, V. A., Reppe, S., Reinholt, F. P., et al. (2007). Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice. J Cell Sci 120, 2785-2795. Roth, L., Koncina, E., Satkauskas, S., Crémel, G., Aunis, D., and Bagnard, D. (2009). The many faces of semaphorins: from development to pathology. Cellular and Molecular Life Sciences 66, 649-666. Sato, N., Maitra, A., Fukushima, N., van Heek, N. T., Matsubayashi, H., Iacobuzio-Donahue, C. A., Rosty, C., and Goggins, M. (2003). Frequent Hypomethylation of Multiple Genes Overexpressed in Pancreatic Ductal Adenocarcinoma. Cancer research 63, 4158-4166. Scharer, C. D., McCabe, C. D., Ali-Seyed, M., Berger, M. F., Bulyk, M. L., and Moreno, C. S. (2009). Genome-Wide Promoter Analysis of the SOX4 Transcriptional Network in Prostate Cancer Cells. Cancer research 69, 709-717. Schilham, M. W., Moerer, P., Cumano, A., and Clevers, H. C. (1997). Sox-4 facilitates thymocyte differentiation. European Journal of Immunology 27, 1292-1295. Schilham, M. W., Oosterwegel, M. A., Moerer, P., Ya, J., de Boer, P. A. J., van de Wetering, M., Verbeek, S., Lamers, W. H., Kruisbeek, A. M., Cumano, A., and Clevers, H. (1996). Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature 380, 711-714. Sekiya, I., Vuoristo, J. T., Larson, B. L., and Prockop, D. J. (2002). In vitro cartilage formation by human adult stem cells from bone marrow stroma defines the sequence of cellular and molecular events during chondrogenesis. Proceedings of the National Academy of Sciences 99, 4397-4402. Shen, R., Pan, S., Qi, S., Lin, X., and Cheng, S. (2010). Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochemical and Biophysical Research Communications 394, 1047-1052. Sinner, D., Kordich, J. J., Spence, J. R., Opoka, R., Rankin, S., Lin, S.-C. J., Jonatan, D., Zorn, A. M., and Wells, J. M. (2007). Sox17 and Sox4 Differentially Regulate β-Catenin/T-Cell Factor Activity and Proliferation of Colon Carcinoma Cells. Molecular and Cellular Biology 27, 7802-7815. Stratton, M. R., Campbell, P. J., and Futreal, P. A. (2009). The cancer genome. Nature 458, 719-724. Takahashi, T., Fournier, A., Nakamura, F., Wang, L.-H., Murakami, Y., Kalb, R. G., Fujisawa, H., and Strittmatter, S. M. (1999). Plexin-Neuropilin-1 Complexes Form Functional Semaphorin-3A Receptors. Cell 99, 59-69. Tamagnone, L., Artigiani, S., Chen, H., He, Z., Ming, G.-l., Song, H.-j., Chedotal, A., Winberg, M. L., Goodman, C. S., Poo, M.-m., et al. (1999). Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates. Cell 99, 71-80. Tao, Y., Kassatly, R. F., Cress, W. D., and Horowitz, J. M. (1997). Subunit composition determines E2F DNA-binding site specificity. Molecular and Cellular Biology 17, 6994-7007. Tavazoie SF, Alarcon C, Oskarsson T, Paudua D, Wang Q, Bos PD, et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147-152. Tsai, K.-W., Wu, C.-W., Hu, L.-Y., Li, S.-C., Liao, Y.-L., Lai, C.-H., Kao, H.-W., Fang, W.-L., Huang, K.-H., Chan, W.-C., and Lin, W.-C. (2011). Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. International Journal of Cancer 129, 2600-2610. Van Der Zwaag, B., Hellemons, A. J. C. G. M., Leenders, W. P. J., Burbach, J. P. H., Brunner, H. G., Padberg, G. W., and Van Bokhoven, H. (2002). PLEXIN-D1, a novel plexin family member, is expressed in vascular endothelium and the central nervous system during mouse embryogenesis. Developmental Dynamics 225, 336-343. -------------------------------------------------------- Part II (p.48) Auernhammer, C. J., and Goke, B. (2011). Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60, 1009-1021. Cohen, T., Herzog, Y., Brodzky, A., Greenson, J. K., Eldar, S., Gluzman-Poltorak, Z., Neufeld, G., and Resnick, M. B. (2002). Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours. The Journal of pathology 198, 77-82. Ehehalt, F., Saeger, H. D., Schmidt, C. M., and Grutzmann, R. (2009). Neuroendocrine tumors of the pancreas. The oncologist 14, 456-467. Gaur, P., Bielenberg, D. R., Samuel, S., Bose, D., Zhou, Y., Gray, M. J., Dallas, N. A., Fan, F., Xia, L., Lu, J., and Ellis, L. M. (2009). Role of Class 3 Semaphorins and Their Receptors in Tumor Growth and Angiogenesis. Clinical Cancer Research 15, 6763-6770. Gitler, A. D., Lu, M. M., and Epstein, J. A. (2004). PlexinD1 and Semaphorin Signaling Are Required in Endothelial Cells for Cardiovascular Development. Developmental Cell 7, 107-116. Kimura, W. (2008). Pathogenesis of endocrine tumors of the pancreas Nihon Geka Gakkai Zasshi 109, 133-142. Lammert, E., Gu, G., McLaughlin, M., Brown, D., Brekken, R., Murtaugh, L. C., Gerber, H.-P., Ferrara, N., and Melton, D. A. (2003). Role of VEGF-A in Vascularization of Pancreatic Islets. Current Biology 13, 1070-1074. Milan, S. A., and Yeo, C. J. (2012). Neuroendocrine tumors of the pancreas. Current opinion in oncology 24, 46-55. Nikolova, G., Jabs, N., Konstantinova, I., Domogatskaya, A., Tryggvason, K., Sorokin, L., et al. (2006). The Vascular Basement Membrane: A Niche for Insulin Gene Expression and beta Cell Proliferation. Developmental Cell 10, 397-405. Oberg, K. (2009). Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Current opinion in endocrinology, diabetes, and obesity 16, 72-78. Pelengaris, S., and Khan, M. (2001). Oncogenic co-operation in beta-cell tumorigenesis. Endocr Relat Cancer 8, 307-314. Rojas, A., Khoo, A., Tejedo, J. R., Bedoya, F. J., Soria, B., Martín, F., and Islam, M. S. (2010). Islet Cell Development. In, (Springer Netherlands), pp. 59-75. Shen, H. C. J., He, M., Powell, A., Adem, A., Lorang, D., Heller, C., Grover, A. C., Ylaya, K., Hewitt, S. M., Marx, S. J., et al. (2009). Recapitulation of Pancreatic Neuroendocrine Tumors in Human Multiple Endocrine Neoplasia Type I Syndrome via Pdx1-Directed Inactivation of Men1. Cancer Res 69, 1858-1866. Staton, C. (2011). Class 3 semaphorins and their receptors in physiological and pathological angiogenesis. Biochem Soc Trans 39, 1565-1570. Sulpice, E., Plouët, J., Bergé, M., Allanic, D., Tobelem, G., and Merkulova-Rainon, T. (2008). Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood 111, 2036-2045. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62782 | - |
dc.description.abstract | 第三類semaphorin 家族分子及其受體plexin、neuropilin 蛋白所負責的訊息傳遞,其功用不止見於神經系統發育過程中的軸突導引,亦常常在不同種類癌症生成或進展扮演重要功能。胰臟腺癌是一種進展快速、易轉移、且致死率高的癌症,雖然已有諸多關於胰臟腺癌致病及轉移的分子機制研究,但第三類semaphorin 家族分子在胰臟腺癌的表現及其造成之影響,僅只有零星的報導。本論文第一部份主要探討第三類semaphorin及其受體plexin、neuropilin 蛋白在胰臟腺癌表現及調控它們表現的機制,首先我們發現:不同於其他癌症通常只表現少數種第三類semaphorin及其受體,胰臟腺癌的腫瘤標本常可見到五種甚至更多種的第三類semaphorin及其受體表現;而這種多個同家族蛋白分子共同表現的現象,並非源於基因複製,而是因為SOX4這個轉錄分子在胰臟腺癌表現,並提高第三類semaphorin及其受體的基因轉錄。當使用RNAi-knockdown方法抑制SOX4在胰臟腺癌細胞株時,第三類semaphorin及其受體的表現量也隨之降低。抑制SOX4表現的細胞株,生長的速度比控制組緩慢,植入老鼠體內時所形成的腫瘤也較小。臨床上的統計顯示,有SOX4表現的胰臟腺癌,表現較多種類的第三類semaphorin及其受體(P=0.033, NPar Kruskal-Wallis one-way 分析) ,病人的五年存活率也較差 (P =0.0409, Kaplan-Meier分析);反之,促進SOX4分解的miR-129-2,在這些病例標本的表現量就少。因此,我們可在胰臟腺癌中建立一個調控模式,意即miR-129-2減少,使得SOX4表現增加,而使第三類semaphorin及其受體的轉錄增加。論文第二部份是檢視第三類semaphorin及其受體在胰臟內分泌腫瘤的表現,結果顯示與胰臟腺癌相異的表現模式,並且semaphorin受體之一的neuropilin 2表現於90%以上的胰臟內分泌腫瘤,可能參與胰臟內分泌腫瘤新生血管的機制。 | zh_TW |
dc.description.abstract | Semaphorin signaling through plexins frequently participates in tumorigenesis and malignant progression in various types of cancer. In particular, the role of semaphorin signaling in pancreatic ductal adenocarcinoma (PDAC) remains unexplored, despite a high likelihood of metastasis and mortality. Unlike other epithelial malignancies that often express a small number of specific genes in the Semaphorin/Plexin family, five or more are often expressed in human PDAC. In the first part of this study, we show that such concomitant expression of these SEMA3/Plexin family members is not a result of gene amplification, but (at least partially) is attributed to increased gene transcription activated by SOX4 neo-expressed in PDAC. Via luciferase promoter activity assay, chromatin-immunoprecipitation, and electrophoresis mobility shift assay, SOX4 is demonstrated to bind to the consensus site at the promoter of each SEMA3 and Plexin gene to enhance transcription activity. Conversely, RNAi-knockdown of SOX4 in PDAC cell lines results in decreased expression of SEMA3/Plexin family members and is associated with restricted tumor growth both in vitro and in SCID mice. Furthermore, SOX4 expression in human PDAC tissues not only parallels with the summed expression of SEMA3/Plexin family members (P=0.033, NPar Kruskal-Wallis one-way analysis) but also correlates with poor survival of PDAC pateints (P=0.0409, Kaplan-Meier analysis). Intriguingly, miR-129-2, which targets SOX4 for degradation, is repressed in some human PDAC cases associated with SOX4 and with a concomitant increase in the expression of SEMA3/Plexin family members. In conclusion, we disclose a miR-129-2/SOX4/Semaphorin-Plexin regulatory axis in the tumorigenesis of pancreatic cancer.
The second part of this study focuses on the expression of SEMA3/Plexin family members in much more infrequent pancreatic neuroendocrine tumors (PNETs), which only accounting for 1-2% of all pancreatic neoplasms. Current concepts of PNET tumorigenesis are nourished from the research in pancreatic endocrine cell development and hereditary PNETs associated with multiple endocrine neoplasia type 1 syndrome (MEN 1), but whether the same molecular alternations exist in sporadic PNETs remained less explored. Neuropilin 2 (NRP2), a receptor for axon guidance molecule semaphorins and vascular endothelial growth factor (VEGF), was reported to be expressed in most PNETs; in this part of study, we utilized immunohistochemistry to examine the expression profile of NRP2 ligands and coreceptors in PNETs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T16:10:16Z (GMT). No. of bitstreams: 1 ntu-102-F88444005-1.pdf: 9714199 bytes, checksum: f5761e41b43015a84e1577356ab39725 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | Acknowledgments………………………………………………………i
Chinese abstract…………………………………………………………………ii English abstract…………………………………………………………….iii PART I. SOX4 transcriptionally regulates multiple SEMA3/Plexin family members and promotes tumor growth in pancreatic cancer 1. INTRODUCTION 1.1 Pathogenesis of pancreatic ductal adenocarcinoma.. 2 1.2 Semaphorins and their receptors........... 2 1.3 Class 3 semaphorins in tumor growth and metastasis 4 2. AIM OF THE STUDY........................... 6 3. MATERIALS AND METHODS 3.1 Ethics Statement.......................... 7 3.2 Case selection .....................................7 3.3 Antibodies................................ 7 3.4 Plasmids and cell lines.................... 8 3.5 Immunohistochemistry....................... 8 3.6 Western blot analysis...................... 8 3.7 Isolation and quantification of mRNA and micro-RNA 9 3.8 Array comparative genomic hybridization.... 9 3.9 Chromatin immunoprecipitation assay....... 10 3.10 Luciferase reporter assay................. 10 3.11 Electrophoretic mobility shift assay..... 11 3.12 RNA interference and selection of stable cell clones ..............................................11 3.13 Cell proliferation, soft agar clonogenic assay, flow cytometry, Brd-U labeling, and TUNEL assay.... 11 3.14 In vivo tumorigenesis assay............... 12 3.15 Detection of K-RAS and SOX4 mutation..... 12 3.16 Statistical analysis..................... 13 4. RESULTS 4.1 Concomitant expression of multiple members of SEMA3 and the PLXN/ NRP receptor complexes in PDAC specimens and cell lines....................................................14 4.2 Individual SEMA3, PLXN, and NRP neo-expression in PDAC specimens does not correlate with patient survival except SEMA3F........................................... 15 4.3 Neo-expression of SOX4 in PDAC correlates with the summed expression of genes from the SEMA3/PLXN/NRP1... 15 4.4 SOX4 activates the transcription of SEMA3 and Plexin genes ........................................ 18 4.5 RNAi-mediated depletion of SOX4 suppresses tumor growth in vitro and in vivo.......................... 18 4.6 Expression of SOX4 is inversely correlated with the expression of microRNA-129-2 in pancreatic cancers and positively correlated with poor survival...... 19 5. DISCUSSION 5.1 Multiple members of SEMA3/Plexin/NRP are expressed in PDAC and activated by SOX4.................... 22 5.2 SOX4 expression in PDAC promotes tumor cell growth 23 5.3 SOX4 expression in human cancers.......... 24 5.4 Regulation of SOX4 expression in PDAC..... 25 6. REFERENCES.................................... 28 PART II. Expression of SEMA3 and their receptor complexes in pancreatic neuroendocrine tumors 1. INTRODUCTION 1.1 Introduction to pancreatic neuroendocrine tumors (PNETs) ................................................38 1.2 Molecular alterations in PNETs.................... 39 1.3 NRP2 expression in PNETs................... 39 2. AIM OF THE STUDY............................. 40 3. MATERIALS AND METHODS 3.1 Case selection............................ 41 3.2 Antibodies................................. 41 3.3 Immunohistochemistry...................... 42 4. RESULTS 4.1 Immunohistochemical stains against NRP2 as well as its lignads and coreceptors in islets of Langerhans....... 43 4.2 Immunohistochemical stains against NRP2 as well as its lignads and coreceptors in PNETs.............. 43 5. DISCUSSION 5.1 Significance of SEMA3, plexins and NRP2 expression in PNETs.......................................... 45 5.2 NRP2, VEGF and VEGFRs expression in PNETs....... 45 5.3 Study limitation.......................... 46 6. REFERENCES.................................... 48 FIGURES Figure 1. A. Multiple members of SEMA3/Plexin family members and NRP1expressed in human PDAC....... 50 Figure 2. Multiple members of SEMA3/Plexin family members and NRP1expressed in human PDAC cell lines.... 52 Figure 3. Kaplan-Meier curves for overall survival correlated with the expression level of each SEMA3 or Plexin ..............................................53 Figure 4. Gene amplification not detected around SEMA3/Plexin/NRP gene loci in two PDAC cell lines..... 54 Figure 5. SOX4 expression in PDAC correlated with the total number of expression of SEMA3/Plexin/NRP1...... 56 Figure 6. SOX4 bound to the promoters of SEMA3 and Plexin in PANC-1 cells................................ 58 Figure 7. SOX4 trans-activated the transcription of SEMA3 and Plexin.................................... 59 Figure 8. Supression of SOX4 resulted in decreased SEMA3 and Plexin expression......................... 61 Figure 9. Reduced in vitro tumor growth by SOX4 suppression ..............................................62 Figure 10. Reduced in vivo tumor growth by SOX4 suppression ..............................................63 Figure 11. Time-course change of ERK1/2 phosphorylation and the cytoplasm-nucleus SOX4 distribution after PD98059 treatment............................................. 64 Figure 12. SOX4 gene is not mutated or amplified in human pancreatic cancer samples and cell lines...... 65 Figure 13. Repressed miR-129-2 associated with expression of SOX4........................................ 66 Figure 14. Expression of SEMA3, PLXNA1-3 PLXND1, neuropilins, VEGF, and VEGFR1-3 in normal islets...... 68 Figure 15. Expression of SEMA3, PLXNA1-3 PLXND1, neuropilins, VEGF, and VEGFR1-3 in PNETs...... 69 TABLES Table 1. Demographic characteristics of patients with PDAC ..............................................70 Table 2. Primer sequences for semi-quantitative RT-PCR .71 Table 3. Primer sequences for real-time quantitative RT-PCR ...............................................72 Table 4. Nucleotide sequences of the PCR primers for end-point PCR after ChIP.................................. 74 Table 5. RNA interference (RNAi) target sequences..... 75 Table 6. Expression of SEMA3, Plexins and NRPs in patients with PDAC....................................... 76 Table 7. Putative SOX4 and E2F1 binding sites in the promoters of SEMA3, plexins and NRP1........... 77 Table 8. Correlation between PDAC nodal metastasis and expression of respective SEMA3, plexins and NRPs...... 78 Table 9. KRAS mutation in PDAC................. 79 Table 10. Demographic characteristics of patients with PNETs and PNECs................................ 80 Table 11. Summary of the immunohistochemical study in PNETs and PNECs.................................... 81 Table 12. SEMA3/Plexin/NRP expression clinical tumor behaviors ..............................................82 | |
dc.language.iso | en | |
dc.title | 第三類 semaphorin及其受體於胰臟外分泌和內分泌腫瘤之表現 | zh_TW |
dc.title | Expression of class 3 semaphorins and their receptor
complexes in pancreatic exocrine and endocrine tumors | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-1 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 許世明 | |
dc.contributor.oralexamcommittee | 林中梧,周祖述,田郁文 | |
dc.subject.keyword | 胰臟腺癌,胰臟內分泌腫瘤,第三類semaphorin,SOX4,轉錄調控, | zh_TW |
dc.subject.keyword | pancreatic ductal adenocarcinoma,pancreatic neuroendocrine tumor,class 3 semaphorin,plexin,SOX4,transcriptional regulation, | en |
dc.relation.page | 82 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-03-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 9.49 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。